Roche’s $7.1B bet on Roivant drug; ADCs and other #ESMO23 dispatch; Highlights from Alzheimer’s confab; Q3 pharma drama; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Be­tween earn­ings sea­son, con­fer­ences and a busy con­gres­sion­al sched­ule, there is tru­ly no bor­ing day here at End­points. This week, we bring you our full ES­MO and CTAD cov­er­age, key take­aways from Q3 re­sults, as well as the splashy Roche deal and a play-by-play look at how Bris­tol My­ers Squibb end­ed up buy­ing Mi­rati.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.